Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy

Takayuki Ohguri, Hajime Imada, Satoshi Nomoto, Katsuya Yahara, Masanori Hisaoka, Hiroshi Hashimoto, Yoshiki Tokura, Katsumasa Nakamura, Yoshiyuki Shioyama, Hiroshi Honda, Hiromi Terashima, Yoiichi Moroi, Masutaka Furue, Yukunori Korogi

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Purpose: To evaluate the effectiveness of curative radiotherapy (RT) plus recombinant interleukin-2 (rIL-2) immunotherapy regarding the treatment results for angiosarcoma of the scalp. Curative resection of angiosarcoma of the scalp is usually difficult because of the diffuse, clinically undetectable local spread. RT is a rational therapeutic approach, because a wide region of the dermis can be treated, while sparing the underlying normal tissues. Recently, the effectiveness of immunotherapy with rIL-2 has also been reported in the treatment of angiosarcoma of the scalp. Methods and Materials: The data of 20 patients with angiosarcoma of the scalp treated with curative RT plus rIL-2 immunotherapy between January 1988 and June 2002 were retrospectively analyzed. The total radiation dose was 70.3 ± 6.9 Gy. The fractions were 2-3 Gy daily, given 5 d/wk. rIL-2 immunotherapy was performed by transcatheter arterial administration in 10 patients, systemic administration in 11 during the course of RT, and intratumoral injection in 10 during and/or after RT; 12 patients received a combination of two. Five patients underwent limited surgery, and concomitant pacilitaxel chemotherapy was also used in 2 patients. Results: The median survival time for overall, local recurrence-free, and distant metastasis-free survival was 36.2, 11.1, and 17.8 months, respectively. Local recurrence developed in 7 patients (35%), 4 of whom also had evidence of distant metastases. An additional 7 patients (35%) developed distant metastases alone. Recurrence within the radiation field was recognized in 2 patients with systemic rIL-2 administration alone (p < 0.05). Arterial or intratumoral administration combined with systemic administration of rIL-2 resulted in better distant metaststasis-free survival rates (p < 0.05). Conclusion: Curative RT plus rIL-2 immunotherapy provided an efficient, effective means of treating angiosarcoma of the scalp. Arterial or intratumoral administration combined with systemic administration of rIL-2 may prolong survival. Additional studies with detailed treatment protocols are recommended.

Original languageEnglish
Pages (from-to)1446-1453
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume61
Issue number5
DOIs
Publication statusPublished - Apr 1 2005

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy'. Together they form a unique fingerprint.

  • Cite this

    Ohguri, T., Imada, H., Nomoto, S., Yahara, K., Hisaoka, M., Hashimoto, H., Tokura, Y., Nakamura, K., Shioyama, Y., Honda, H., Terashima, H., Moroi, Y., Furue, M., & Korogi, Y. (2005). Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy. International Journal of Radiation Oncology Biology Physics, 61(5), 1446-1453. https://doi.org/10.1016/j.ijrobp.2004.08.008